Oral oncology最新文献

{"title":"Comment on “Osteoradionecrosis as a complication following post-operative intensity-modulated radiation therapy or proton therapy for oral cavity cancer”","authors":"Erkan Topkan, Efsun Somay, Duriye Ozturk, Ugur Selek","doi":"10.1016/j.oraloncology.2025.107649","DOIUrl":"10.1016/j.oraloncology.2025.107649","url":null,"abstract":"","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"169 ","pages":"Article 107649"},"PeriodicalIF":3.9,"publicationDate":"2025-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144996310","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reframing 3D-printed tissue retraction devices for global head and neck radiotherapy: Reflections on the GUARD trial","authors":"Cherdpong Choenklang, Schawanya K. Rattanapitoon, Nav La, Nathkapach K. Rattanapitoon","doi":"10.1016/j.oraloncology.2025.107651","DOIUrl":"10.1016/j.oraloncology.2025.107651","url":null,"abstract":"","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"169 ","pages":"Article 107651"},"PeriodicalIF":3.9,"publicationDate":"2025-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144996311","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of adjuvant radiotherapy in relation to tumor size for bone-invasive pT4aN0 oral squamous cell carcinoma – A retrospective observational matched cohort study","authors":"Friedrich Mrosk ,&nbsp;Inka Hampe ,&nbsp;Victoria Vertic ,&nbsp;Maximilian Richter ,&nbsp;Erin Sprünken ,&nbsp;Lukas Mödl ,&nbsp;Marcus Beck ,&nbsp;Jan Oliver Voss ,&nbsp;Christian Doll ,&nbsp;Jakob Fenske ,&nbsp;Carsten Rendenbach ,&nbsp;Max Heiland ,&nbsp;Steffen Koerdt","doi":"10.1016/j.oraloncology.2025.107670","DOIUrl":"10.1016/j.oraloncology.2025.107670","url":null,"abstract":"<div><h3>Objective</h3><div>Oral squamous cell carcinoma (OSCC) with bone invasion are staged as pT4a, potentially upstaging smaller tumors. This study aimed to evaluate the oncological benefit of postoperative radiotherapy (PORT) in pT4aN0 OSCC with respect to tumor size and without other risk factors.</div></div><div><h3>Methods</h3><div>This retrospective matched cohort study included pT4aN0 OSCC patients with bone invasion treated surgically (R0) between 2010 and 2022. Each case was 1:1 matched to a pT1–3 N0 OSCC patient based on tumor size, but without bone invasion. The primary endpoint was overall survival (OS), secondary endpoints included the recurrence-free survival and outcome predictors.</div></div><div><h3>Results</h3><div>A total of 156 patients were analyzed (78 per group). There were no statistically significant differences in 3-year OS between both groups in general (78.2%, 95%CI: 68.6–87.8 vs. 80.0%, 95%CI: 68.4–91.6). After stratification for pT2 criteria, there was also no significant difference between both groups if PORT was omitted (63.9%, 95%CI: 44.2–92.4 vs. 70.5%, 95%CI: 55.0–90.0). Multivariate analysis identified age and poor differentiation (grade III) as significant predictors of worse OS, while PORT showed no independent survival benefit.</div></div><div><h3>Conclusion</h3><div>In small OSCC staged pT4a due to bone invasion and lacking other risk factors, PORT demonstrated no statistically significant improvement in OS when matched for tumor size. Further prospective trials and larger cohorts are warranted to confirm these findings.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"169 ","pages":"Article 107670"},"PeriodicalIF":3.9,"publicationDate":"2025-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144996306","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on: “Survival patterns and prognostic stratification based on distant metastasis characteristics in oral squamous cell carcinoma”","authors":"Longzhou Li ,&nbsp;Jun Geng","doi":"10.1016/j.oraloncology.2025.107641","DOIUrl":"10.1016/j.oraloncology.2025.107641","url":null,"abstract":"","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"169 ","pages":"Article 107641"},"PeriodicalIF":3.9,"publicationDate":"2025-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144932834","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Financial instability, insurance, and transportation influence timely head and neck cancer care in the United States: Patient and healthcare worker perspectives","authors":"Sana Batool ,&nbsp;Elisabeth E. Hansen ,&nbsp;Rosh K.V. Sethi ,&nbsp;Eleni M. Rettig ,&nbsp;Laura A. Goguen ,&nbsp;Donald J. Annino ,&nbsp;Ravindra Uppaluri ,&nbsp;Heather A. Edwards ,&nbsp;Daniel L. Faden ,&nbsp;Gezzer Ortega ,&nbsp;Daniel Dohan ,&nbsp;Amanda J. Reich ,&nbsp;Regan W. Bergmark","doi":"10.1016/j.oraloncology.2025.107607","DOIUrl":"10.1016/j.oraloncology.2025.107607","url":null,"abstract":"<div><h3>Introduction</h3><div>Delays in head and neck cancer (HNC) diagnosis and treatment and financial burdens of care are often rooted in social determinants of health (SDOH), such as financial instability, socioeconomic status (SES), health insurance status, and transportation barriers. While these factors are well recognized, their underlying impact on access to care remains underexplored; this qualitative study aims to investigate how these SDOH facilitate or hinder HNC care through insights from patients and healthcare workers (HCWs) in the United States, to identify targets for intervention.</div></div><div><h3>Methods</h3><div>Semi-structured interviews were conducted with patients with newly diagnosed HNC, and HCWs caring for these patients, between June 2022 and July 2023. Audio-recorded interviews were transcribed. Iterative deductive and inductive analysis was performed using NVivo 1.7.1 with two coders to identify mechanisms by which SDOH shaped HNC care processes.</div></div><div><h3>Results</h3><div>A total of 72 participants were interviewed, including 42 patients with HNC (mean age 57 years, range 19–81; 64 % female; 81 % white) and 30 HCWs (mean age 42 years, range 20–68; 77 % female; 83 % white). In analysis, three mechanisms were identified: (1) socioeconomic instability forces patients to make critical choices, (2) the added burden of addressing health insurance gaps falls on patients, and (3) transportation-related financial and logistical barriers disrupt care processes.</div></div><div><h3>Conclusion</h3><div>Financial instability, insurance gaps, and transportation challenges create barriers to HNC care for disadvantaged patients. Understanding these SDOH can improve care timeliness and patient experiences.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"169 ","pages":"Article 107607"},"PeriodicalIF":3.9,"publicationDate":"2025-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144932832","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on “Prediction of clinical outcomes of immune checkpoint inhibitors in advanced head and neck cancer directly from histopathology slides using inferred transcriptomics”","authors":"Xueyuan Peng,&nbsp;Yingxia Xie,&nbsp;Yuan Liu","doi":"10.1016/j.oraloncology.2025.107644","DOIUrl":"10.1016/j.oraloncology.2025.107644","url":null,"abstract":"","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"169 ","pages":"Article 107644"},"PeriodicalIF":3.9,"publicationDate":"2025-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144932833","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A phase 1/1b study of lenvatinib and cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma","authors":"Lara A. Dunn ,&nbsp;Alan L. Ho ,&nbsp;Loren S. Michel ,&nbsp;Winston Wong ,&nbsp;Juliana Eng ,&nbsp;Iris Zhi ,&nbsp;Kenneth K. Ng ,&nbsp;Anuja Kriplani ,&nbsp;James Fetten ,&nbsp;Sofia S. Haque ,&nbsp;Nora Katabi ,&nbsp;Zhigang Zhang ,&nbsp;David G. Pfister ,&nbsp;Eric J. Sherman","doi":"10.1016/j.oraloncology.2025.107524","DOIUrl":"10.1016/j.oraloncology.2025.107524","url":null,"abstract":"<div><h3>Background</h3><div>Despite overexpression of EGFR in head/neck squamous cell carcinoma (HNSCC), cetuximab monotherapy has limited benefit. Lenvatinib is a multi-targeted receptor tyrosine kinase inhibitor with activity against FGFRs1-4, involved in resistance to EGFR inhibition. We evaluated lenvatinib in combination with cetuximab in recurrent/metastatic (R/M) HNSCC.</div></div><div><h3>Methods</h3><div>This phase 1/1b, single-institution trial (2018–2022) investigated dose de-escalation in patients with advanced HNSCC and cutaneous squamous cell carcinoma (cSCC) treated with standard cetuximab dosing and lenvatinib in 3 dose levels (0 [24 mg], −1 [20 mg], −2 [14 mg]) orally daily in 3 + 3 design. The primary objective was to determine maximum tolerated dose (MTD) of lenvatinib plus cetuximab. The expansion phase included additional patients with HNSCC receiving MTD. Exploratory endpoints included objective response rate (ORR) and median progression-free survival (mPFS) in HNSCC patients receiving MTD.</div></div><div><h3>Results</h3><div>The dose de-escalation phase included 12 evaluable patients. There were no dose-limiting toxicities (DLTs) on level 0; 3/6 patients were removed following the 28-day DLT period due to toxicities (all with HNSCC). At level −1, 0/6 pts (5 HNSCC/1 cSCC) had a DLT, establishing level −1 as MTD. The expansion phase included 5 evaluable patients. Of 10 evaluable HNSCC patients receiving MTD, 7 had a partial response (70 % ORR; mPFS, 4.1 m [range 1.4–17.5]). Related grade 3 adverse events included hypertension, oral mucositis, dysphagia, oral cavity fistula, and pharyngeal fistula.</div></div><div><h3>Conclusions</h3><div>The MTD of lenvatinib 20 mg daily with cetuximab appears active in R/M HNSCC with an impressive preliminary ORR, warranting further evaluation of this combination.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"169 ","pages":"Article 107524"},"PeriodicalIF":3.9,"publicationDate":"2025-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144932831","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advancing AI-driven pathology in oral cancer: opportunities for enhanced TIL assessment and clinical integration.","authors":"Zekai Yu, Ziye Zhuang, Xiaohong Zhao, Hao Chi","doi":"10.1016/j.oraloncology.2025.107586","DOIUrl":"10.1016/j.oraloncology.2025.107586","url":null,"abstract":"","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"168 ","pages":"107586"},"PeriodicalIF":3.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144794927","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on: \"Cisplatin ototoxicity and hydration schedules''.","authors":"Gokhan Koker, Gulhan Ozcelik","doi":"10.1016/j.oraloncology.2025.107545","DOIUrl":"10.1016/j.oraloncology.2025.107545","url":null,"abstract":"","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"168 ","pages":"107545"},"PeriodicalIF":3.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144799785","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Osteoradionecrosis as a complication following post-operative intensity-modulated radiation therapy or proton therapy for oral cavity cancer.","authors":"Teeradon Treechairusame, Annu Singh, Edward Christopher Dee, Jung Hun Oh, Pengpeng Zhang, Jianping Xiong, Eric Aliotta, Amir H Safavi, Yingzhi Wu, Cao Caineng, Kevin Sine, Dennis Mah, Andy Shim, Haibo Lin, Jung J Kang, Chaiojung Jillian Tsai, Daphna Y Gelblum, Yao Yu, Sean McBride, Nadeem Riaz, Kaveh Zakeri, Linda Chen, Achraf Shamseddine, Winston Wong, Lara A Dunn, Loren S Michel, Eric J Sherman, Alan L Ho, Joseph M Huryn, SaeHee K Yom, Ian Ganly, Jennifer R Cracchiolo, Marc A Cohen, Richard J Wong, Cherry L Estilo, Nancy Y Lee","doi":"10.1016/j.oraloncology.2025.107581","DOIUrl":"10.1016/j.oraloncology.2025.107581","url":null,"abstract":"<p><strong>Objective: </strong>To report the prevalenceof osteoradionecrosis (ORN) in oral cavity (OC) cancer patients following intensity-modulation radiation therapy (IMRT) or proton therapy (PRT).</p><p><strong>Methods: </strong>A retrospective study was conducted on consecutive cohort of OC cancer patients treated with IMRT or PRT for squamous cell carcinoma (SCC). Patient information and treatment related variables were collected from medical records. Patients who developed ORN were uniformly graded using CTCAE v5. Cox proportional hazards model was used to compare risk factors between IMRT and PRT.Kaplan-Meier method was used to estimate the cumulative incidence (CI) of ORN.</p><p><strong>Results: </strong>A total of 479 OC SCC patients (426 treated with IMRT and 53 treated with PRT) were included in this study. The median follow-up time was 35 months (IQR, 17-68 months). The prevalence of ORN was similar between groups: 11% (47/426) in the IMRT group (21 Grade 1, 13 Grade 2, 13 Grade 3) and 11.3% (6/53) in the PRT group (2 Grade 1, 3 Grade 2, 1 Grade 3). The median time to ORN development was shorter following IMRT [13 months (IQR, 9-39)] compared to PRT [28 months (IQR, 4-42)].The 3-year CI of any grade ORN was 9.6 % and 11.4 % for IMRT and PRT (log-rank P-value = 0.550), respectively. On univariable analysis, smoking history (P = 0.072), tumor stage (P = 0.011), tumor with mandibular invasion (P = 0.007), and extent of mandibular intervention (P < 0.001) was associated with ORN development. On multivariable analysis, the extent of mandibular intervention remained a significant risk factor (P < 0.001).</p><p><strong>Conclusion: </strong>In this single-institution study, we found a similar prevalence of ORN following IMRT (11%) and PRT (11.3 %) in OC cancer patients.</p>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"168 ","pages":"107581"},"PeriodicalIF":3.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144812218","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}